Stimwave HF SCS Pilot Study (HFSCS)

Prospective, Clinical Pilot Study of High Frequency Wireless Spinal Cord Stimulation (SCS) in the Treatment of Chronic Pain With The Freedom Spinal Cord Stimulatory

The purpose of this study is to observe the efficacy of stimulation on over all pain relief as reported in an initial cohort of 6 patients treated with the Freedom High Frequency Spinal Cord Stimulator (SCS) System for low back and/or leg pain.

Study Overview

• Status: Completed
• Conditions: FBSS
• Intervention / Treatment: Device: Implant procedure, Freedom Spinal Cord Stimulation System

Detailed Description

This is a non-blinded, short-term study for a maximum duration of 12 weeks in which 6 patients will receive a Freedom SCS System. Subjects will have chronic, intractable pain of the trunk and/or lower limbs refractory to standard medical treatment; including unilateral or bilateral pain. Stimulators will be placed in the epidural space and over exiting nerve roots at vertebrae levels:

A. Bilateral T9-T10 epidural; B. Bilateral L1-L4 epidural. All Patients will be treated below perception threshold with High Frequency settings (10.000 Hz, 30 μs).

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Belgium
  • West-Vlaanderen
    • Roeselare, West-Vlaanderen, Belgium, 8800
      • AZ Delta

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

1. Inclusion Criteria:

   A. Subject is ≥ 18 years of age at time of informed consent;

   B. Subjects have been diagnosed with chronic, intractable pain of the trunk and/or lower limbs with a VAS > 5cm (on a 10-cm scale);

   C. Subject diagnosis with chronic pain refractory to conventional medical management for at least 6 months prior to enrollment;

   D. Based on the medical opinion of the Principal Investigator, there is no evidence of anatomic abnormalities that could jeopardize the placement of the device or pose a hazard to the subject;

   E. Subject is willing to undergo surgical implant procedure, attend visits as scheduled, and comply with the study requirements;

   F. Based on the opinion of the Principal Investigator, subject is willing and able to operate the patient programmer, recharging equipment, diary and has the ability to undergo study assessments and provide accurate responses;

   G. Based on the opinion of the implanter, subject is a good surgical candidate for the implant procedure;

   H. Subject is male or non-pregnant female;

   I. Subject is deemed to be neuro-psycho-socially appropriate for implantation therapies based of the assessment of the investigator, using face-to-face encounters and the psychological testing described in the measures;

   J. Patient is capable of giving informed consent;

   K. Patient lives within reasonable distance from the study site (circumference of 75 km).

2. Exclusion Criteria:

A. Obvious mechanical instability related to pain (diagnosed by imaging taken within the past 6 months);

B. Malignancies;

C. Subject has post-herpetic neuralgia (shingles);

D. Subject has an active systemic infection or is immune-compromised.

E. Based on the medical opinion of the Principal Investigator the subject has other psychological conditions (e.g., psychosis, suicidal ideation, borderline personality disorder, somatization, narcissism), other health conditions (e.g., substance abuse, another chronic condition requiring the regular use of opioid medication), or other legal concerns that would preclude his/her enrollment in the study or potentially confound the results of the study;

F. Subject is currently enrolled in or plans to enroll in any concurrent drug and/or device study while participating in this study;

G. Insulin-dependent diabetic who is not controlled through diet and/or medication;

H. Bleeding complications or coagulopathy issues;

I. Pregnant/lactating or not using adequate birth control;

J. A life expectancy of less than one year;

K. Any active implanted device whether turned off or on;

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: HF DRG; HF DRG Implants	Device: Implant procedure, Freedom Spinal Cord Stimulation System; A needle is carefully inserted near the spinal cord. The stimulator is then slide through the needle to lay close to the spinal cord. The end of the stimulator is then sutured underneath the skin of the back.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary Efficacy Outcome (VAS)	The primary outcome is defined as the percentage of subjects who respond (50% average or more pain relief for back and leg pain) to SCS therapy at the end of 12 weeks post-implant of the system as compared to baseline with no increase in medication. The primary outcome will be measured with the VAS (100 mm line).	12 weeks post-implant
Primary Safety Outcome (Adverse Events)	Incidence and severity of device related adverse events during the study	12 weeks post-implant

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
VAS	Percentage change from baseline in VAS for back and leg pain	12 weeks post-implant
ODI	Change from baseline in functionality using the ODI score	12 weeks post-implant

Collaborators and Investigators

• Sponsor: Stimwave Technologies

Study record dates

Study Major Dates

• Study Start: June 1, 2016
• Primary Completion (Actual): May 1, 2017
• Study Completion (Actual): May 1, 2017

Study Registration Dates

• First Submitted: May 20, 2016
• First Submitted That Met QC Criteria: May 26, 2016
• First Posted (Estimate): June 1, 2016

Study Record Updates

• Last Update Posted (Actual): June 8, 2017
• Last Update Submitted That Met QC Criteria: June 7, 2017
• Last Verified: June 1, 2017

More Information

Terms related to this study

• Other Study ID Numbers: 30-00178